ALVERON PHARMA CLOSES SERIES A ROUND TO ADVANCE A CYCLODEXTRIN BASED PROCOAGULANT MEDICINE INTO THE CLINIC Alveron Pharma, a newly incorporated company established by Okklo Life Sciences BV and Sanquinnovate (part of Sanquin), is pleased to announce the closing of a EUR 6.5M Series A financing round led by Thuja together with Waterman Ventures and …
Okklo Life Sciences B.V. (Nijmegen, The Netherlands) and SolAeroMed Inc. (Calgary, Canada) have signed an agreement to join forces in the field of cyclodextrins and pulmonary diseases. The collaboration aims to optimize the development of novel cyclodextrins for the treatment of cystic fibrosis. In this partnership SolAeroMed will test proprietary cyclodextrins designed by Okklo for …
Nijmegen/Amsterdam, January 10, 2017 Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. Okklo Life Sciences B.V. (Nijmegen, The Netherlands) and Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) today announced that they have signed an agreement regarding the further development and commercialization of their first in …
Nijmegen/Amsterdam, May 14 2016 RedMedTech Ventures funding enables further development of cyclodextrines. Sanquin Blood Supply Foundation and Okklo Life Sciences BV extend their cardiovascular program. Okklo Life Sciences BV and Sanquin Blood Supply Foundation (Amsterdam) announced today that they are going to expand their research and licensing agreement. Funding from RedMedTech Ventures allows the …